The second IL-10 peak observed at day 7 in CD4+ cells prompted us to study IL-10 production by other cell populations at this time point, using tumor-free mice, since equivalent results had been observed in lymphoid organs from tumor-free and tumor-bearing mice. This evidence concerns the gene CD4 and neoplasm.